3Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims 19-38 are pending.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 19-38 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for making compounds, does not reasonably provide enablement for using the compounds for treating any and all diseases as claimed.
For example, it is not seen where in the specification enabling disclosure is found for treating any disease other than MyD88 driven disorder ABC DLBCL. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.
The determination that "undue experimentation" would have been needed to make and use the claimed invention is not a single, simple factual determination. Rather, it is a conclusion reached by weighing all the relevant factual considerations.
Enablement is considered in view of the Wands factors (MPEP 2164.01 (a)). These include: (1) breadth of the claims; (2) nature of the invention; (3) state of the prior art; (4) amount of direction provided by the inventor; (5) the level of predictability in the art; (6) the existence of working examples; (7) quantity of experimentation needed to make or use the invention based on the content of the disclosure; and (8) relative skill in the art.
All of the factors have been considered with regard to the claims, with the most relevant factors discussed below:
The recited compounds are bifunctional compounds, which function to recruit IRAK kinases to E3 Ubiquitin Ligase for degradation. IRAK degraders are heterobifunctional small molecules, such as PROTACs—Proteolysis Targeting Chimeras) designed to destroy Interleukin-1 Receptor-Associated Kinases, primarily IRAK4 and IRAK1. The formula for the bifunctional compounds has substituents layered on top of substituents encompassing large number of conceivable structures that vary widely in physical and chemical properties. These properties are known in the art to have major effect on pharmacological properties relevant for the intended use. For example see Troup, Current strategies for the design of PROTAC linkers: a critical review, Explor Target Antitumor Ther. 2020;1:273-312, at page 273, for significance of the linkers linking the two functional portions of PROTACs. The
PNG
media_image1.png
306
698
media_image1.png
Greyscale
is an example of the wide scope of the recited active ingredients.
Biological properties are unpredictable and are ultimately tide to the chemical structure. See “Role of the Development Scientist in Compound Lead Selection and Optimization” by Venkatesh, J. Pharm. Sci. 89, 145-154 (2000) (p. 146, left column). Likewise, J. G. Cannon, Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, Volume I: Principles and Practice, Wiley-Interscience 1995, pp. 783-802, 784, teaches many caveats in analog design and states
PNG
media_image2.png
95
310
media_image2.png
Greyscale
According to Churcher, Journal of Medicinal Chemistry Volume 61, Issue 2, 25 January 2018, the underpinning science of PROTAC offers a real opportunity to break free of the shackles of receptor pharmacology which has limited much of modern small molecule drug discovery. Churcher also points to outstanding challenges which lie ahead of this technology. Churcher concludes with the statement ‘We wait expectantly’.
Similarly, according to, Wang, Degradation of proteins by PROTACs and other strategies, Acta Pharmaceutica Sinica B 2020;10(2):207e238, PROTACs have entered a period of rapid development, creating a new direction in biopharmaceutical industry; PROTACs have many unique advantages, but have several inherent flaws, for example, due to the high molecular weight and complex structure of PROTACs, their distribution and metabolism within the tissue must be limited by the transmembrane permeability of the PROTAC.
Likewise, Watt tilted ‘Targeted protein degradation in vivo with proteolysis targeting chimeras: current status and future considerations, Drug Discov Today Technol, 31 (2019), pp. 69-80, teaches that ‘this (PROTAC) field will continue to rapidly evolve over coming years particularly as the repertoire of E3 ligase binders expands and tissue restricted pharmacology is explored, and so the clinical evaluation of PROTACs will inform the next steps for this exciting new modality. The potential of PROTACs as a new therapeutic modality has been highlighted in the existing literature. The focus to date has been on understanding the preclinical profile of PRO TACs that degrade a range of protein targets.
Nunes titled ‘Targeting IRAK4 for Degradation with PROTACs”, ACS Med. Chem. Lett., 10, 1081-1085, June 14, 2019, represents state of the art and teaches the unpredictable nature of the claimed subject matter of ‘method of treating an IRAK-mediated disorder, disease, or condition’ with bifunctional molecules. Nunes reports that a small molecule PROTAC approach achieving potent intracellular degradation of the kinase IRAK4. The PROTAC-induced IRAK4 degradation is dependent on binding to VHL E3 Ubiquitin Ligase) and is reversed upon blocking proteasome activity. However, compound 9 (IRAK4 PROTAC) was not found to possess a differentiated pharmacological profile over PF-06650833 in a phenotypic assay measuring a variety of inflammatory cytokines (Figure 5b). In addition, the IRAK4 knockout phenotype reported with dermal fibroblasts could not be reproduced with compound 9 (Figure 5d). Therefore, more work is required to understand the biology of this target. It is clear, however, that development of new modalities such as PROTACs to target IRAK4 may not only support the understanding of IRAK4 biology but could also lead to the development of new therapeutic agents to treat inflammatory and oncological disease.
The above state of the art references teaches that while teaching the ‘potential’ for IRAK degraders, also teach the unpredictability in the art.
However, according to Wang (see above), Kymera's KYM-001 (IRAK4 PROTAC similar Nunes noted above) is a class of orally effective IRAK4 selective degrading agent that can cause tumor retraction in the MYD88 mutant ABC DLBCL model.
Working Example is limited to a cellular assay that measures the targeted degradation of the IRAK4: ‘IRAK4 MSD Degradation in OCI-LY10’. This Example-24 Table 6 at page 1017 teaches a gradation of activity for the recited active ingredients.
Further according to disclosure (see published Application column A page 326)
-[1066] In some instances, degradation of IRAK4 alone is not sufficient to kill the MYD88 L265P mutant DLBCL cell line OCI-LY10 either in vitro or as a flank xenograft in vivo. In some embodiments, a non-IMiD-based degraders effects IRAK degradation in MYD88 mutant ABC DLBCL cell line tumor xenografts but without causing regression. This is consistent with literature demonstrating no effect on growth of OCI-LY10 or other MYD88 mutant lines when the gene encoding IRAK4 is removed at the DNA level using CRISPR/Cas9 editing (Phelan et al. “A multiprotein supercomplex controlling oncogenic signaling in lymphoma” Nature, 2018, 7718:387-391).
[1069] In certain embodiments, the combination of IRAK kinase degradation with IKZF1 and IKZF3 degradation in an all-in-one IMiD-based IRAK4 degrader shows potent, single agent activity versus MYD88 mutant ABC DLBCL cell lines in vitro and OCI-LY10 xenograft in vivo
The above admitted to situation with respect to IRAK4 degraders and use is consistent with the teachings of Churcher, Wang, Watt and N Nunes and consistent with the well-established principle that “the scope of enablement varies inversely with the degree of unpredictability of the factors involved,” and physiological activity is generally considered to be an unpredictable factor. See In re Fisher, 427 F. 2d 833, 839, 166, USPQ 18, 24 (CCPA 1970). Genentech Inc. v. Novo Nordisk A/S (CA FC) 42 USPQ2d 1001, states “a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion” and “[p]atent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable”.
Taken together the instant claim 19 to any and all
PNG
media_image3.png
22
306
media_image3.png
Greyscale
or as per claim 19 or claims 20-25 finds little support in the specification.
MPEP 2164.03 states: “The scope of the required enablement varies inversely with the degree of predictability involved. In cases involving unpredictable factors, such as most chemical reactions and physiological activity, more may be required. In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) (contrasting mechanical and electrical elements with chemical reactions and physiological activity). See also In re Wright, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993); In re Vaeck, 947 F.2d 488, 496, 20 USPQ2d 1438, 1445 (Fed. Cir. 1991).
MPEP 2164.01(a) states, “A conclusion of Iack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. ln re Wright, 999 F.2d 1557,1562, 27 USPQ 2d 1510, 1513 (Fed. Cir. 1993).'' That conclusion is clearly justified here. Thus, undue experimentation would be required to make and use Applicants' invention.
.
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.
Yu, MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis. Blood, 2021 Mar 25;137(12):1615-1627.
Shuai, Chronic lymphocytic leukemia (CLL) is not a MyD88-driven disorder in the same way that Waldenström macroglobulinemia or lymphoplasmacytic lymphoma is . Blood Cancer Journal (2020) 10:86.
Minderman, MYD88-driven disorders are actually most strongly linked to specific non-Hodgkin lymphomas (NHLs), rather than Hodgkin lymphoma, Blood Cancer Journal, (2023) 13:125, 1-10.
Note: This action takes into consideration, discussions with attorney Todd Macklin on 1015/2026 with respect to the scope of the claims and the disclosure in the post filing date Kymera, 37th ACS National Medicinal Chemistry Symposium New York City, NY, June 26th– 29th, 2022.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIZAL S CHANDRAKUMAR whose telephone number is (571)272-6202. The examiner can normally be reached M-F 8-5 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/NIZAL S CHANDRAKUMAR/Primary Examiner, Art Unit 1625